Kyi, C. K., Spira, A., Carbone, D. P., Johnson, M. L., Henick, B. S., Johnson, B., Borghaei, H., Mahipal, A., Hecht, J. R., Catenacci, D., Liao, C.-Y., Shergill, A., Memmott, R., Presley, C., Jaroslavsky, J., Schenk, D., Jooss, K., Ferguson, A. R., & Goldman, J. W. (2022). 736MO Personalized, off-the-shelf KRAS neoantigen-specific immunotherapy for the treatment of advanced solid tumors: Clinical benefit associated with decreases in ctDNA (SLATE-KRAS). Annals of Oncology, 33, S880. https://doi.org/10.1016/j.annonc.2022.07.862

Ingham, M., Blay, J.-Y., Baird, J., D’Silva, D., O’Keefe, K., Kong, R., Spiegel, R., Wahba, M., & Weetall, M. (2022). 1528TiP A phase II/III study evaluating the efficacy and safety of unesbulin in advanced leiomyosarcoma (SUNRISELMS). Annals of Oncology, 33, S1243–S1244. https://doi.org/10.1016/j.annonc.2022.07.1917

Dimitriou, F., Hassel, J. C., Orloff, M., Hughes, I., Kapiteijn, E., Mehmi, I., Montazeri, K., Johnson, D. B., Grover, P., Gerard, C. L., Simeone, E., Gaudy Marqueste, C., Cheng, P., Long, G. V., Carvajal, R. D., & Dummer, R. (2022). 832P Treatment sequence with tebentafusp (tebe) and anti-PD1/ipilimumab (PD1+IPI) in HLA-A2*02:01 patients (pts) with metastatic uveal melanoma (mUM). Annals of Oncology, 33, S929. https://doi.org/10.1016/j.annonc.2022.07.958

Berlin, A. (2022). Close Encounters of the First Kind: An Interdisciplinary Ethics of Care Approach Mitigates Moral Injury and Family Division in the Midst of Covid-19. Journal of Pain and Symptom Management, 64(3), e159–e164. https://doi.org/10.1016/j.jpainsymman.2021.03.028

Prebet, T., Goldberg, A. D., Jurcic, J. G., Khaled, S., Dail, M., Feng, Y., Green, C., Li, C., Ma, C., Medeiros, B. C., Yan, M., & Grunwald, M. R. (2022). A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia. Leukemia & Lymphoma, 63(9), 2180–2188. https://doi.org/10.1080/10428194.2022.2057484

Yap, T. A., Moore, K. N., Patel, M., Henick, B. S., Do, D., Iheanacho, A., Zhang, H., Roche, M., Newberry, K., Hsieh, A., & Juric, D. (2022). 491TiP A first-in-human phase I/II study of BLU-222, a potent, selective CDK2 inhibitor in patients with CCNE1-amplified or CDK4/6 inhibitor-resistant advanced solid tumors. Annals of Oncology, 33, S765. https://doi.org/10.1016/j.annonc.2022.07.619

Sato, T., Ikeguchi, A. P., Nathan, P., Carvajal, R. D., Shoushtari, A. N., Gajewski, T. F., Hassel, J. C., Rioth, M., Leyvraz, S., Daniels, G. A., Hernandez-Aya, L., Johnson, D. B., Kim, K., Piulats Rodriguez, J. M., Cowey, C. L., Lockwood, S., Collins, L., Karakuzu, O., Sacco, J. J., & Butler, M. O. (2022). 843P Long-term survivors on tebentafusp in phase II trial of previously treated patients with metastatic uveal melanoma. Annals of Oncology, 33, S934–S935. https://doi.org/10.1016/j.annonc.2022.07.969

Seymour, J. F., Kipps, T. J., Eichhorst, B. F., D’Rozario, J., Owen, C. J., Assouline, S., Lamanna, N., Robak, T., de la Serna, J., Jaeger, U., Cartron, G., Montillo, M., Mellink, C., Chyla, B., Panchal, A., Lu, T., Wu, J. Q., Jiang, Y., Lefebure, M., … Kater, A. P. (2022). Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. Blood, 140(8), 839–850. https://doi.org/10.1182/blood.2021015014

Ryu, Y. K., Ricker, E. C., Soderquist, C. R., Francescone, M. A., Lipsky, A. H., & Amengual, J. E. (2022). Targeting CD38 with Daratumumab Plus Chemotherapy for Patients with Advanced-Stage Plasmablastoid Large B-Cell Lymphoma. Journal of Clinical Medicine, 11(16), 4928. https://doi.org/10.3390/jcm11164928

Wang, P. H., Washburn, R., Maniar, R., Mu, M., Ringham, O., Kratchmarov, R., Henick, B. S., & Reiner, S. L. (2022). Cutting Edge: Promoting T Cell Factor 1+ T Cell Self-Renewal to Improve Programmed Cell Death Protein 1 Blockade. The Journal of Immunology, 209(4), 660–664. https://doi.org/10.4049/jimmunol.2200317

Leuva, H., Zhou, M., Brau, N., Brown, S. T., Mundi, P., Rosenberg, T.-C. M., Luhrs, C., Bates, S. E., Park, Y.-H. A., & Fojo, T. (2022). Influence of Cancer on COVID-19 Incidence, Outcomes, and Vaccine Effectiveness: A Prospective Cohort Study of U.S. Veterans. Seminars in Oncology, 49(5), 363–370. https://doi.org/10.1053/j.seminoncol.2022.07.005

Gordon, K. G., Carvajal, R. D., Graham, S. L., & Houghton, O. M. (2022). The reporting of uveal melanoma cases to the cancer registry in North Carolina. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.877599

Maniar, A., Wei, A. Z., Dercle, L., Bien, H. H., Fojo, T., Bates, S. E., & Schwartz, L. H. (2022). Assessing Outcomes in NSCLC: Radiomic analysis, kinetic analysis and circulating tumor DNA. Seminars in Oncology, 49(3–4), 298–305. https://doi.org/10.1053/j.seminoncol.2022.06.002

Moriconi, C., Dzieciatkowska, M., Roy, M., D’Alessandro, A., Roingeard, P., Lee, J. Y., Gibb, D. R., Tredicine, M., McGill, M. A., Qiu, A., La Carpia, F., Francis, R. O., Hod, E. A., Thomas, T., Picard, M., Akpan, I. J., Luckey, C. J., Zimring, J. C., Spitalnik, S. L., & Hudson, K. E. (2022). Retention of functional mitochondria in mature red blood cells from patients with sickle cell disease. British Journal of Haematology, 198(3), 574–586. Portico. https://doi.org/10.1111/bjh.18287

Alvarez-Breckenridge, C., Markson, S. C., Stocking, J. H., Nayyar, N., Lastrapes, M., Strickland, M. R., Kim, A. E., de Sauvage, M., Dahal, A., Larson, J. M., Mora, J. L., Navia, A. W., Klein, R. H., Kuter, B. M., Gill, C. M., Bertalan, M., Shaw, B., Kaplan, A., Subramanian, M., … Carter, S. L. (2022). Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition. Cancer Immunology Research, 10(8), 996–1012. https://doi.org/10.1158/2326-6066.cir-21-0870

Meyer, A. E., Stelloh, C., Pulakanti, K., Burns, R., Fisher, J. B., Heimbruch, K. E., Tarima, S., Furumo, Q., Brennan, J., Zheng, Y., Viny, A. D., Vassiliou, G. S., & Rao, S. (2022). Combinatorial genetics reveals the Dock1-Rac2 axis as a potential target for the treatment of NPM1;Cohesin mutated AML. Leukemia, 36(8), 2032–2041. https://doi.org/10.1038/s41375-022-01632-y

Dioun, S., Chen, L., Melamed, A., Gockley, A., St. Clair, C. M., Hou, J. Y., Khoury‐Collado, F., Hershman, D. L., & Wright, J. D. (2022). Uptake and outcomes of sentinel lymph node mapping in women undergoing minimally invasive surgery for endometrial cancer. BJOG: An International Journal of Obstetrics & Gynaecology, 129(9), 1591–1599. Portico. https://doi.org/10.1111/1471-0528.17085

Bailey, S., Wang, Q., Kong, C. Y., Stone, K., Veluswamy, R., Bates, S. E., Smith, C. B., Wisnivesky, J. P., & Sigel, K. (2022). Optimizing the use of adjuvant chemotherapy in non-small cell lung cancer patients with comorbidities. Current Problems in Cancer, 46(4), 100867. https://doi.org/10.1016/j.currproblcancer.2022.100867

Sanborn, R. E., Pishvaian, M. J., Callahan, M. K., Weise, A., Sikic, B. I., Rahma, O., Cho, D. C., Rizvi, N. A., Sznol, M., Lutzky, J., Bauman, J. E., Bitting, R. L., Starodub, A., Jimeno, A., Reardon, D. A., Kaley, T., Iwamoto, F., Baehring, J. M., Subramaniam, D. S., … Keler, T. (2022). Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors. Journal for ImmunoTherapy of Cancer, 10(8), e005147. https://doi.org/10.1136/jitc-2022-005147

Vanguri, R. S., Fenn, K. M., Kearney, M. R., Wang, Q., Guo, H., Marks, D. K., Chin, C., Alcus, C. F., Thompson, J. B., Leu, C.-S., Hibshoosh, H., Kalinsky, K. M., Mathews, J. C., Nadeem, S., Hollmann, T. J., & Connolly, E. P. (2022). Tumor Immune Microenvironment and Response to Neoadjuvant Chemotherapy in Hormone Receptor/HER2+ Early Stage Breast Cancer. Clinical Breast Cancer, 22(6), 538–546. https://doi.org/10.1016/j.clbc.2022.04.002

Gounder, M. M., Razak, A. A., Somaiah, N., Chawla, S., Martin-Broto, J., Grignani, G., Schuetze, S. M., Vincenzi, B., Wagner, A. J., Chmielowski, B., Jones, R. L., Riedel, R. F., Stacchiotti, S., Loggers, E. T., Ganjoo, K. N., Le Cesne, A., Italiano, A., Garcia del Muro, X., Burgess, M., … Attia, S. (2022). Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Clinical Oncology, 40(22), 2479–2490. https://doi.org/10.1200/jco.21.01829

Diggs, A., Sia, T. Y., Huang, Y., Gockley, A., Melamed, A., Khoury-Collado, F., St. Clair, C., Hou, J. Y., Hershman, D. L., & Wright, J. D. (2022). Utilization and outcomes of adjuvant therapy for stage II and III uterine leiomyosarcoma. Gynecologic Oncology, 166(2), 308–316. https://doi.org/10.1016/j.ygyno.2022.05.018

Kahn, J. M., Zhang, X., Kahn, A. R., Castellino, S. M., Neugut, A. I., Schymura, M. J., Boscoe, F. P., & Keegan, T. H. M. (2022). Racial Disparities in Children, Adolescents, and Young Adults with Hodgkin Lymphoma Enrolled in the New York State Medicaid Program. Journal of Adolescent and Young Adult Oncology, 11(4), 360–369. https://doi.org/10.1089/jayao.2021.0131

Palmer, C. D., Rappaport, A. R., Davis, M. J., Hart, M. G., Scallan, C. D., Hong, S.-J., Gitlin, L., Kraemer, L. D., Kounlavouth, S., Yang, A., Smith, L., Schenk, D., Skoberne, M., Taquechel, K., Marrali, M., Jaroslavsky, J. R., Nganje, C. N., Maloney, E., Zhou, R., … Jooss, K. (2022). Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nature Medicine, 28(8), 1619–1629. https://doi.org/10.1038/s41591-022-01937-6

Rippel, N., Tremblay, D., Zubizarreta, N., Podoltsev, N., Gotlib, J., Heaney, M., Kuykendall, A., O’Connell, C., Shammo, J. M., Fleischman, A., Kremyanskaya, M., Hoffman, R., Mesa, R., Yacoub, A., & Mascarenhas, J. (2022). Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database. Leukemia Research, 119, 106903. https://doi.org/10.1016/j.leukres.2022.106903

Mullangi, S., Aviki, E. M., Chen, Y., Robson, M., & Hershman, D. L. (2022). Factors Associated With Cancer Treatment Delay Among Patients Diagnosed With COVID-19. JAMA Network Open, 5(7), e2224296. https://doi.org/10.1001/jamanetworkopen.2022.24296

Kukafka, R., Pan, S., Silverman, T., Zhang, T., Chung, W. K., Terry, M. B., Fleck, E., Younge, R. G., Trivedi, M. S., McGuinness, J. E., He, T., Dimond, J., & Crew, K. D. (2022). Patient and Clinician Decision Support to Increase Genetic Counseling for Hereditary Breast and Ovarian Cancer Syndrome in Primary Care. JAMA Network Open, 5(7), e2222092. https://doi.org/10.1001/jamanetworkopen.2022.22092

Ayeni, O. A., O’Neil, D. S., Pumpalova, Y. S., Chen, W. C., Nietz, S., Phakathi, B., Buccimazza, I., Čačala, S., Stopforth, L. W., Farrow, H. A., Mapanga, W., Joffe, M., Chirwa, T., McCormack, V., Jacobson, J. S., Crew, K. D., Neugut, A. I., Ruff, P., & Cubasch, H. (2022). Impact of HIV infection on survival among women with stage I‐III breast cancer: Results from the South African breast cancer and HIV outcomes study. International Journal of Cancer, 151(2), 209–221. Portico. https://doi.org/10.1002/ijc.33981

Beauchemin, M. P., Raghunathan, R. R., Accordino, M. K., Cogan, J. C., Kahn, J. M., Wright, J. D., & Hershman, D. L. (2022). New persistent opioid use among adolescents and young adults with sarcoma. Cancer, 128(14), 2777–2785. Portico. https://doi.org/10.1002/cncr.34238

Gold, J. A. W., Tolu, S. S., Chiller, T., Benedict, K., & Jackson, B. R. (2021). Incidence of Invasive Fungal Infections in Patients Initiating Ibrutinib and Other Small Molecule Kinase Inhibitors—United States, July 2016–June 2019. Clinical Infectious Diseases, 75(2), 334–337. https://doi.org/10.1093/cid/ciab1026

Bose, S., Lee, T., Choi, S., Fazlollahi, L., Rasiej, M. J., Schwartz, G. K., & Ingham, M. (2022). CDK4/6 Inhibition With Anti–PD-1 Checkpoint Blockade Induces Major Response in Aggressive Classic Kaposi Sarcoma After Previous Progression on Anti-PD–1 Alone. JCO Precision Oncology, 6. https://doi.org/10.1200/po.21.00550

Asgary, R., Garland, V., Ro, V., Stribling, J. C., & Waldman, R. (2022). A systematic review of effective strategies for chronic disease management in humanitarian settings; opportunities and challenges. Preventive Medicine, 161, 107154. https://doi.org/10.1016/j.ypmed.2022.107154

Papachristodoulou, A., & Abate-Shen, C. (2022). Precision intervention for prostate cancer: Re-evaluating who is at risk. Cancer Letters, 538, 215709. https://doi.org/10.1016/j.canlet.2022.215709

Biermann, J., Melms, J. C., Amin, A. D., Wang, Y., Caprio, L. A., Karz, A., Tagore, S., Barrera, I., Ibarra-Arellano, M. A., Andreatta, M., Fullerton, B. T., Gretarsson, K. H., Sahu, V., Mangipudy, V. S., Nguyen, T. T. T., Nair, A., Rogava, M., Ho, P., Koch, P. D., … Izar, B. (2022). Dissecting the treatment-naive ecosystem of human melanoma brain metastasis. Cell, 185(14), 2591-2608.e30. https://doi.org/10.1016/j.cell.2022.06.007

Park, J., Artin, M. G., Lee, K. E., Pumpalova, Y. S., Ingram, M. A., May, B. L., Park, M., Hur, C., & Tatonetti, N. P. (2022). Deep learning on time series laboratory test results from electronic health records for early detection of pancreatic cancer. Journal of Biomedical Informatics, 131, 104095. https://doi.org/10.1016/j.jbi.2022.104095

Broustas, C. G., Mukherjee, S., Pannkuk, E. L., Laiakis, E. C., Fornace, A. J., & Amundson, S. A. (2022). Effect of the p38 Mitogen-Activated Protein Kinase Signaling Cascade on Radiation Biodosimetry. Radiation Research, 198(1). https://doi.org/10.1667/rade-21-00240.1

Park, K., Sabari, J., Haura, E. B., Shu, C. A., Spira, A., Salgia, R., Reckamp, K. L., Sanborn, R. E., Govindan, R., Bauml, J. M., Curtin, J. C., Xie, J., Roshak, A., Lorenzini, P., Millington, D., Thayu, M., Knoblauch, R. E., & Cho, B. C. (2022). MO4-1 Management of infusion-related reactions in patients receiving amivantamab in the CHRYSALIS study. Annals of Oncology, 33, S482. https://doi.org/10.1016/j.annonc.2022.05.104

Liu, C., Lin, B., Wu, M., Song, Y., Ke, T., Chou, Y., Liu, C., Lin, C., Radojcic, V., Drake, C., & Yen, H. (2022). Adoptive transfer of IL‐4 reprogrammed Tc17 cells elicits anti‐tumour immunity through functional plasticity. Immunology, 166(3), 310–326. Portico. https://doi.org/10.1111/imm.13473

McGuinness, J. E., Ro, V., Mutasa, S., Pan, S., Hu, J., Trivedi, M. S., Accordino, M. K., Kalinsky, K., Hershman, D. L., Ha, R. S., & Crew, K. D. (2022). Use of a convolutional neural network-based mammographic evaluation to predict breast cancer recurrence among women with hormone receptor-positive operable breast cancer. Breast Cancer Research and Treatment, 194(1), 35–47. https://doi.org/10.1007/s10549-022-06614-3

Henick, B. S., Villarroel-Espindola, F., Datar, I., Sanmamed, M. F., Yu, J., Desai, S., Li, A., Aguirre-Ducler, A., Syrigos, K., Rimm, D. L., Chen, L., Herbst, R. S., & Schalper, K. A. (2022). Quantitative tissue analysis and role of myeloid cells in non-small cell lung cancer. Journal for ImmunoTherapy of Cancer, 10(7), e005025. https://doi.org/10.1136/jitc-2022-005025

Mishkin, A. D., Cheung, S., Capote, J., Fan, W., & Muskin, P. R. (2022). Survey of Clinician Experiences of Telepsychiatry and Tele-Consultation-Liaison Psychiatry. Journal of the Academy of Consultation-Liaison Psychiatry, 63(4), 334–344. https://doi.org/10.1016/j.jaclp.2021.10.005

Vecchione, A., Madley, R., Danzl, N., Borsotti, C., Marharlooei, M. K., Li, H.-W., Nauman, G., Ding, X., Ho, S.-H., Fousteri, G., & Sykes, M. (2022). T1D patient-derived hematopoietic stem cells are programmed to generate Tph, Tfh, and autoimmunity-associated B cell subsets in human immune system mice. Clinical Immunology, 240, 109048. https://doi.org/10.1016/j.clim.2022.109048

Ryu, Y. K., & Amengual, J. E. (2022). Easy does it! New EZH2 inhibitor SHR2554 is safe and active in relapsed or refractory lymphoma. The Lancet Haematology, 9(7), e463–e465. https://doi.org/10.1016/s2352-3026(22)00169-7

Li, W., & Shen, M. M. (2022). Prostate cancer cell heterogeneity and plasticity: Insights from studies of genetically-engineered mouse models. Seminars in Cancer Biology, 82, 60–67. https://doi.org/10.1016/j.semcancer.2021.06.016

Nooka, A., Costa, L., Gasparetto, C., Richardson, P., Siegel, D., Chari, A., Lentzsch, S., Jagannath, S., & Mikhael, J. (2022). Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert Roundtable. Clinical Lymphoma Myeloma and Leukemia, 22(7), e526–e531. https://doi.org/10.1016/j.clml.2022.01.014

Kumar, S., Baizer, L., Callander, N. S., Giralt, S. A., Hillengass, J., Freidlin, B., Hoering, A., Richardson, P. G., Schwartz, E. I., Reiman, A., Lentzsch, S., McCarthy, P. L., Jagannath, S., Yee, A. J., Little, R. F., & Raje, N. S. (2022). Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee. Blood Cancer Journal, 12(6). https://doi.org/10.1038/s41408-022-00695-5

Tremblay, D., Srisuwananukorn, A., Ronner, L., Podoltsev, N., Gotlib, J., Heaney, M. L., Kuykendall, A., O’Connell, C. L., Shammo, J. M., Fleischman, A., Mesa, R., Yacoub, A., Hoffman, R., Moshier, E., Zubizarreta, N., & Mascarenhas, J. (2022). European LeukemiaNet Response Predicts Disease Progression but Not Thrombosis in Polycythemia Vera. HemaSphere, 6(6), e721. https://doi.org/10.1097/hs9.0000000000000721

Etra, A., Gergoudis, S., Morales, G., Spyrou, N., Shah, J., Kowalyk, S., Ayuk, F., Baez, J., Chanswangphuwana, C., Chen, Y.-B., Choe, H., DeFilipp, Z., Gandhi, I., Hexner, E., Hogan, W. J., Holler, E., Kapoor, U., Kitko, C. L., Kraus, S., … Levine, J. E. (2022). Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification. Blood Advances, 6(12), 3707–3715. https://doi.org/10.1182/bloodadvances.2022007296

Bose, S., Schwartz, G. K., & Ingham, M. (2022). Novel Therapeutics in the Treatment of Uterine Sarcoma. American Society of Clinical Oncology Educational Book, 42, 900–909. https://doi.org/10.1200/edbk_350541

Chakraborty, R., Siddiqi, R., Willson, G., Gupta, S., Asghar, N., Husnain, M., Aljama, M. A., Behera, T. R., Anwer, F., Perrot, A., & Riaz, I. B. (2022). Impact of autologous transplantation on survival in patients with newly diagnosed multiple myeloma who have high‐risk cytogenetics: A meta‐analysis of randomized controlled trials. Cancer, 128(12), 2288–2297. Portico. https://doi.org/10.1002/cncr.34211